$JAGX

Jaguar Health, Inc.

Jaguar Health develops prescription drugs derived from plants for people with gastrointestinal diseases, including rare and orphan conditions. Its wholly owned subsidiary Napo Pharmaceuticals focuses on human health and crofelemer, while Napo Therapeutics, established in Milan, Italy in 2021, works to expand global access to crofelemer and develop therapies for rare gastrointestinal conditions. Jaguar is headquartered in San Francisco, California. Jaguar’s products include Mytesi, an FDA-approved crofelemer tablet for noninfectious diarrhea in adults with HIV/AIDS receiving antiretroviral therapy; Canalevia-CA1, a crofelemer tablet for chemotherapy-induced diarrhea in dogs; and Gelclair, a prescription gel for oral mucositis pain. Future Pak is the exclusive marketer of Mytesi and Canalevia-CA1 in the United States, while Jaguar continues to manufacture them. Jaguar is developing crofelemer powder for oral solution for microvillus inclusion disease and short bowel syndrome with intestinal failure, and NP-300 for infectious diarrhea. Its Magdalena Biosciences joint venture develops plant-derived prescription medicines for mental health indications.

1
2
3

No SEC Form 4 filings for $JAGX in the last 30 days.

See all $JAGX insider activity →
Med

Jaguar Health Inc (JAGX) Q3 2026 Earnings Call Highlights: Debt Cut by $10 Million

Jaguar Health (JAGX) reported Q3 2026 net loss decreased by $3.8M to $5.8M, debt reduced by $10M. CEO Conti cited clinical data showing crofelemer's efficacy in rare intestinal diseases. CFO Lizak noted revenue fell to $500K due to licensing agreement. Management highlighted blockbuster potential in global intestinal failure market.

Jaguar Health Reports Third Quarter 2026 Financials

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jaguar Health Reports Third Quarter 2026 Financials Jaguar’s rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical mile

Jaguar Health 3Q 2026: Revenue $2.34M, EPS ($9.23) — 10-Q Summary

Jaguar Health reported 3Q 2026 revenue of $2.34M, down 24% YoY, with net loss narrowing to $6.31M. License revenue rose to $1.8M, while product revenue declined due to lower Mytesi sales. R&D expenses decreased slightly, and commercial costs dropped significantly after transferring Mytesi and Canalevia commercialization to Woodward. The company's pivotal pediatric MVID trial is ongoing, with clinical work continuing for crofelemer powder.

JAGX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning JAGX (Jaguar Health, Inc.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 3 bearish.

Recent JAGX coverage spans corporate actions, earnings and financial news.

What's driving JAGX

AlphAI scores every news story that mentions JAGX with an AI model for sentiment and relevance, and aggregates insider trades from Jaguar Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $JAGX

Score
$JAGXMedEarnings

Jaguar Health Reports Third Quarter 2026 Financials

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jaguar Health Reports Third Quarter 2026 Financials Jaguar’s rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical mile

Jaguar Health 3Q 2026: Revenue $2.34M, EPS ($9.23) — 10-Q Summary

Jaguar Health reported 3Q 2026 revenue of $2.34M, down 24% YoY, with net loss narrowing to $6.31M. License revenue rose to $1.8M, while product revenue declined due to lower Mytesi sales. R&D expenses decreased slightly, and commercial costs dropped significantly after transferring Mytesi and Canalevia commercialization to Woodward. The company's pivotal pediatric MVID trial is ongoing, with clinical work continuing for crofelemer powder.

$JAGXLowShareholder vote

Jaguar Health, Inc. (JAGX): Submission of Matters to a Vote of Security Holders

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders San Francisco, CA (November 6, 2026): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced the voting results of the Company’s November 6, 2026

$JAGXLowDividend· special

Jaguar Health, Inc. paid a special one time dividend of one share of Series R Convertible Preferred Stock, par value $0.0001 per share for each share of…

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on October 15, 2026, Jaguar Health, Inc. (the “Company” or “Jaguar”) paid a special one time dividend of one share of Series R Convertible Preferred Stock, par value $0.0001 per share (the “Series O Preferred Stock”) for each share

Jaguar Health Approves Sixfold Increase to 2014 Plan Share Reserve

Jaguar Health approved a sixfold increase to its 2014 Stock Incentive Plan share reserve, effective after a November 6 meeting. If Proposal 3 is approved, the reserve will be 2,273,154 shares; if not, it will be 4,260 shares. Maximum shares issuable through incentive stock options will be 163,998 in either case, according to the company.

Jaguar Health, Inc. filed with the Securities and Exchange Commission a definitive proxy statement in connection with the Company’s special meeting of…

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 8, 2026, Jaguar Health, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a definitive proxy statement (the “Proxy Statement”) in connection with the Company’s special meeting of stockholders, to be held on Novem

Related tickers